drugset / Trial / NCT00489190

APIDRA Registration Study

NCT00489190

Phase 4 Completed 45 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To collect effectiveness and safety data during the treatment with Apidra glulisine (HMR1964) by means of subcutaneous injections to patients with Diabetes Mellitus 1st type during 12 weeks-active phase.

Timeline

Start
2005-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin glulisine Protein / enzyme biologic Subcutaneous